Cittelly et al demonstrated that breast cancer overexpressing HER-2 exhibited resistance to tamoxifen through the upregulation of B-cell CLL/lymphoma 2 (BCL-2) and the suppression of miR-15a/16 induced by tamoxifen (10). This evidence concerns the gene ERBB2 and breast carcinoma.